MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "L-threo-34-dihydroxyphenylserine(L-DOPS)"

  • 2019 International Congress

    Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients

    K. Hay, K. Mcdonell, P. Trujillo, M. Donahue, N. van Wouwe, D. Claassen (Nashville, TN, USA)

    Objective: To assess safety, tolerability, and central effects of L-Dihydroxyphenylserine (L-DOPS), in Parkinson’s disease (PD) patients treated with DOPA decarboxylase inhibition. Background: Norepinephrine (NE) is…
  • 2019 International Congress

    Changes in Supine Blood Pressure with Long Term Use of Droxidopa

    S. Gorny, L. Hewitt, A. Lindsten, M. Karnik-Henry, S. Kymes, A. Favit (Deerfield, IL, USA)

    Objective: To determine the long-term effects of droxidopa use on supine blood pressure (BP) in patients with neurogenic orthostatic hypotension (nOH). Background: nOH is a…
  • 2018 International Congress

    Droxidopa and Midodrine Treatment Persistence in Patients with Orthostatic Hypotension

    S. Kymes, K. Jackson, M. Widolff, C. Sullivan, L. Hewitt, S. Raj (Deerfield, IL, USA)

    Objective: To determine the treatment persistence of droxidopa and midodrine in patients with orthostatic hypotension (OH) or neurogenic orthostatic hypotension (nOH) when medication cost was…
  • 2017 International Congress

    Patient-Reported Outcomes in a Prospective Real-World Study of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension

    S. Kymes, C. François, K. McLeod, A. Duhig, A. Ogbonnaya, A. Quillen, J. Cannon, C. Shibao, B. Yue, I. Biaggioni (Deerfield, IL, USA)

    Objective: To assess the effect of droxidopa treatment on function, depression, and health-related quality of life (HRQoL) in patients with neurogenic orthostatic hypotension (nOH). Background:…
  • 2017 International Congress

    Effect of Droxidopa Treatment on Fear of Falling in Patients With Neurogenic Orthostatic Hypotension: Clinical Trial and “Real World” Results

    S. Kymes, C. François, G. Peng, G. Rowse, S. Isaacson (Deerfield, IL, USA)

    Objective: To assess the impact of droxidopa on fear of falling in patients with symptomatic neurogenic orthostatic hypotension (nOH) in 2 studies. Background: nOH results…
  • 2016 International Congress

    Systematic literature review of droxidopa in clinical trials for neurogenic orthostatic hypotension (nOH) in parkinsonism

    S. Tashiro, K. Dashtipour, J.J. Chen, K. Frei, E. Rashidian (Loma Linda, CA, USA)

    Objective: The aim of this study was to review the published evidence for the efficacy, safety, and dosing practices of droxidopa treatment for symptomatic neurogenic…
  • 2016 International Congress

    Impact of neurogenic orthostatic hypotension on healthcare utilization and costs associated with falls in Parkinson’s disease

    C. Francois, I. Biaggioni, C.A. Shibao, A. Ogbonnaya, H.C. Shih, E. Farrelly, A. Ziemann, A. Duhig (Deerfield, IL, USA)

    Objective: To compare demographic and clinical characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD and neurogenic…

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley